To start your customized experience click the start button
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2017
CURE Communications Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Feature Video
Dr Shannon Westin, a clinical investigator at the MD Anderson Cancer Center, discusses PARP inhibition for patients with deleterious or suspected deleterious germline BRCA-mutated (as detected by an FDA-approved test) advanced ovarian cancer who have been treated with three or more prior lines of chemotherapy.
Angeles Alvarez Secord, MD, discusses the risk of recurrence of ovarian cancer with her patient, Michelle Berke. Dr Secord also explains how BRCA mutations play a role in the disease course and how she determines the best treatment option once cancer recurs.
Michelle Berke shares her story regarding genetic testing. Angeles Alvarez Secord, MD, explains why it is important for family members of patients with ovarian cancer to be tested.
Angeles Alvarez Secord, MD, recalls how she explained treatment options to her patient, Michelle Berke. Michelle offers her perspectives on the difficulty of processing the information.
Angeles Alvarez Secord, MD, revisits her initial conversations about surgery and chemotherapy with her patient, Michelle Berke, following Michelle’s ovarian cancer diagnosis. They also discuss decisions regarding maintenance therapy.
Michelle Berke talks with Angeles Alvarez Secord, MD, about the symptoms she experienced leading up to her ovarian cancer diagnosis. Dr. Secord provides guidance on the signs and symptoms that women should not ignore.
Anya Khomenko reflects on her journey as a patient and survivor of ovarian cancer and suggests why patients need to advocate for themselves and remain positive that there are always new treatment options on the horizon.
Justin Chura, MD, explains his protocol for monitoring patients for recurrence and discusses how he talks to patients about maintenance therapy versus surveillance.                          
Justin Chura, MD, provides an overview of maintenance therapy in ovarian cancer and discusses the role for PARP inhibitors in this setting.
Justin Chura, MD, explains how gene mutations play a role in ovarian cancer, and remarks on new opportunities in treating ovarian cancer with PARP (poly [ADP-ribose] polymerase) inhibitors.
Justin Chura, MD, discusses his initial approach to treating ovarian cancer. Anya Khomenko, survivor of ovarian cancer, advises patients on how to become educated on new therapeutic options and prepare for follow-up appointments.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment


Healthcare Professional

Not Applicable